首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration.
【24h】

The kinetics of tolerance induction by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration.

机译:通过非消耗性抗CD4单克隆抗体(RIB 5/2)加上静脉内供体同种异体抗原给药诱导耐受的动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: CD4+ T cells play an essential role in allograft rejection. The monoclonal anti-rat CD4 antibody, RIB 5/2, has been shown to modulate the CD4 glycoprotein without eliminating the recipient T cells. We have successfully induced tolerance to rat heart allografts by recipient pretreatment with a single dose of RIB 5/2 plus intravenous administration of donor splenocytes. In this study, we explored whether this potent regimen could induce tolerance to the more resistant kidney and skin allografts. Furthermore, we examined the kinetics and requirements for tolerance to be met by a single dose of RIB 5/2 plus i.v. alloantigen. METHODS: The efficacy of a single i.p. dose of 20 mg/kg RIB 5/2 plus i.v. donor antigen (25x10(6) splenocyte) pretreatment 0, 21, or 40 days before receipt of an MHC-mismatched Lewis (RT1l) to Buffalo (RT1b) rat cardiac, renal, or skin allograft was studied. Another group of Buffalo recipients treated with RIB 5/2 plus an i.v. alloantigen +/-thymectomy received kidney transplants after 40 days. Attempts to prevent tolerance used interleukin-2 or prior sensitization. Mixed lymphocyte cultures, cytotoxic assays, and precursor frequencies of helper and cytotoxic cells, by limiting dilution analysis, serially measured in vitro cell-mediated immunity. RESULTS: RIB 5/2 administration combined with i.v. alloantigen 21 days before induced tolerance to heart and kidney allografts but did not prolong skin graft survival. In contrast, kidney allografts delayed for 40 days after pretreatment were acutely rejected and survival was not affected by the thymectomy. MLC, CTL, and pTH, and pCTL precursor frequencies from recipients of long-term grafts were specifically suppressed to donor, but not third party, alloantigen. CONCLUSION: A single dose of the nondepleting anti-CD4 monoclonal antibody, RIB 5/2, plus i.v. alloantigen is a potent inducer of tolerance to heart and kidney, but not skin, allografts. The RIB 5/2-induced donor unresponsiveness to a delayed kidney or cardiac allograft is time dependent but can be prolonged if specific alloantigen is present. Suppression of cell-mediated allo-immune responsiveness correlates with allograft acceptance.
机译:背景:CD4 + T细胞在同种异体移植排斥中起重要作用。已显示单克隆抗大鼠CD4抗体RIB 5/2可以调节CD4糖蛋白而不会消除受体T细胞。通过用单剂量的RIB 5/2进行受体预处理以及静脉内给予供体脾细胞,我们已经成功地诱导了对大鼠心脏同种异体移植的耐受性。在这项研究中,我们探讨了这种有效方案是否可以诱导对更耐受的肾脏和皮肤同种异体移植的耐受性。此外,我们检查了单剂量的RIB 5/2加静脉注射可满足的动力学和耐受性要求。同种抗原。方法:单次腹腔注射的疗效剂量为20 mg / kg RIB 5/2加上i.v.研究了供体抗原(25x10(6)脾细胞)在接受MHC不匹配的Lewis(RT11)至Buffalo(RT1b)大鼠心脏,肾脏或皮肤同种异体移植之前0、21或40天的预处理。另一组接受RIB 5/2加上静脉注射的水牛接受者。 40天后,同种异体抗原+/-胸腺切除术接受了肾脏移植。尝试使用白介素2或事前敏化预防耐受。通过有限稀释分析,连续测量体外细胞介导的免疫力,进行混合的淋巴细胞培养,细胞毒性测定以及辅助细胞和细胞毒性细胞的前体频率。结果:RIB 5/2管理与i.v.同种异体抗原在诱导对心脏和肾脏同种异体移植的耐受之前21天,但没有延长皮肤移植物的存活时间。相比之下,预处理后延迟了40天的同种异体肾移植被急性排斥,并且胸腺切除术不影响生存。来自长期移植受者的MLC,CTL,pTH和pCTL前体频率被特异地抑制了供体而非同种异体抗原。结论:单剂量的非消耗性抗CD4单克隆抗体RIB 5/2,加上静脉注射。同种异体抗原是对心脏和肾脏但不是皮肤同种异体移植耐受的有效诱导剂。 RIB 5/2诱导的供体对延迟的肾脏或心脏同种异体移植无反应是时间依赖性的,但如果存在特定的同种异体抗原则可以延长。细胞介导的同种免疫反应性的抑制与同种异体移植的接受有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号